Cantor Fitzgerald Initiates Coverage On Tenax Therapeutics with Overweight Rating, Announces Price Target of $35

Cantor Fitzgerald analyst Olivia Brayer Saunders has initiated coverage on Tenax Therapeutics (NASDAQ: TENX) with an Overweight rating. The firm has set a price target of $35 for the company's stock.